Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 27, Number 3—March 2021

Synopsis

Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa

Sarah V. LeavittComments to Author , Karen R. Jacobson, Elizabeth J. Ragan, Jacob Bor, Jennifer Hughes, Tara C. Bouton, Tania Dolby, Robin M. Warren, and Helen E. Jenkins
Author affiliations: Boston University, Boston, Massachusetts, USA (S.V. Leavitt, K.R. Jacobson, E.J. Ragan, J. Bor, T.C. Bouton, H.E. Jenkins); Boston Medical Center, Boston (K.R. Jacobson, E.J. Ragan, T.C. Bouton); University of the Witwatersrand, Johannesburg, South Africa (J. Bor); Stellenbosch University, Stellenbosch, South Africa (J. Hughes, R.M. Warren); Brown University, Providence, Rhode Island, USA (T.C. Bouton); Green Point Tuberculosis Laboratory, Cape Town, South Africa (T. Dolby); South African Medical Research Council Centre for Tuberculosis Research, Cape Town (R.M. Warren); Department of Science and Technology–National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Cape Town (R.M. Warren)

Main Article

Table 4

Multivariable logistic regression for factors associated with sample submitted from a TB hospital <1 y after diagnosis of RR TB, Western Cape, South Africa, 2012–2014*

Characteristic Overall, n = 2,831
 Cape Town, n = 1,846
 Outside Cape Town, n = 985
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Location
Cape Town Referent Referent Referent
Other
 5.7 (4.8–6.8)
 <0.01
NA
NA
Sex
F Referent Referent Referent
M
 1.2 (1.0–1.4)
 0.03
1.2 (1.0–1.5)
 0.07
1.2 (0.9–1.6)
 0.27
Age, y
15–34 Referent Referent Referent
35–54 1.1 (0.9–1.3) 0.43 1.2 (0.9–1.5) 0.14 0.9 (0.7–1.3) 0.55
>55
 0.8 (0.6–1.2)
 0.24
1.0 (0.6–1.6)
 0.95
0.6 (0.3–1.0)
 0.05
Type of TB
Pulmonary only Referent Referent Referent
Extrapulmonary only 1.0 (0.5–1.7) 0.98 0.8 (0.4–1.7) 0.63 1.3 (0.5–3.5) 0.53
Both
 2.7 (1.8–4.2)
 <0.01
3.7 (2.3–5.9)
 <0.01
1.1 (0.5–2.4)
 0.85
Results of most recent smear from <30 d of first RR TB–positive sample
Negative Referent Referent Referent
Scanty positive 1.4 (1.0–1.8) 0.03 1.7 (1.2–2.4) <0.01 1.0 (0.6–1.6) >0.99
Positive + 1.5 (1.1–2.1) <0.01 1.6 (1.1–2.2) 0.02 1.5 (0.9–2.8) 0.16
Positive ++ 1.8 (1.3–2.5) <0.01 1.5 (1.0–2.3) 0.06 3.0 (1.5–6.4) <0.01
Positive +++ 2.1 (1.7–2.7) <0.01 1.9 (1.4–2.5) <0.01 3.5 (2.2–5.8) <0.01
Unknown
 1.2 (0.9–1.7)
 0.19
1.2 (0.8–1.9)
 0.29
1.2 (0.7–2.1)
 0.56
Quarter of RR TB diagnosis† 0.98 (0.95–1.02) 0.29 0.95 (0.92–0.99) 0.02 1.04 (0.98–1.10) 0.20

*Patients without second-line drug resistance who attended >2 visits. All analyses adjusted for no. of visits <1 y after diagnosis. Excludes 47 patients who are missing data on age, sex, or both. NA, not applicable; OR, odds ratio; RR, rifampin-resistant; TB, tuberculosis.
†Estimated change per quarter (i.e., 3 mos).

Main Article

Page created: January 29, 2021
Page updated: February 21, 2021
Page reviewed: February 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external